Drug Approval | July 30, 2024
Dr. Reddy's receives positive CHMP opinion from EMA for its proposed Rituximab biosimilar
Dr. Reddy's had previously received the EU GMP certificate for its Rituximab drug substance
Dr. Reddy's had previously received the EU GMP certificate for its Rituximab drug substance
Dr. Reddy's Laboratories has reported total income of Rs. 7,672.7 crores during the period ended June 30, 2024
The discussion at the fourth session was centered on the fusion of academic rigor and industrial pragmatism as a key to pioneering solutions for sustainable and prosperous future
Rusan’s API facility in Ankleshwar is GMP approved by other stringent international agencies as well
Acquisition provides Ligand with the royalty rights to QARZIBA, a highly differentiated, commercial oncology drug marketed in 35 countries by global pharmaceutical company Recordati S.p.A.
Achievement of This Major Milestone Further Simplifies and Strengthens the Company and Positions Viatris to Achieve its Key Priorities and Accelerate Future Growth
Felzartamab demonstrated positive interim results from the Phase 2 IgA nephropathy (IgAN) study
Submission based on positive SUPERNOVA Phase III trial data which demonstrated a statistically significant reduction in the incidence of COVID?19 in an immunocompromised patient population
Imfinzi also recommended for patients with mismatch repair deficient disease
Ace Lab conducts 170 batches of testing per month and has capacity to do more than 250 batches per month
Subscribe To Our Newsletter & Stay Updated
